Linked Life Data

18471160

Source:http://linkedlifedata.com/resource/pubmed/id/18471160

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-5-12
pubmed:abstractText
Candida species constitute the majority of nosocomial fungal pathogens in non-neutropenic patients. Candida infections are still connected with substantial mortality. Recent epidemiological observations indicate a shift to non-albicans species, especially because of a rise of infections caused by C. glabrata, which frequently shows fluconazole-resistance. New therapeutic options like caspofungin, as the first licensed echinocandin, new broad-spectrum azoles, and lipid preparations of amphotericin B emerged in the last decade as efficient alternatives to fluconazole and amphotercin B deoxycholate. In invasive candidiasis, a delayed treatment initiation is associated with an increased mortality, thus risk stratification and empirical therapy strategies become vitally important. This review reflects the efficacy of caspofungin in the treatment of Candida infections, especially in the setting of empirical therapy in critically ill patients, and considers the option of de-escalation to fluconazole.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1439-0507
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
51 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
35-46
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
pubmed:affiliation
Department of Anesthesiology, University of Heidelberg, Im Neuenheimer Feld, Heidelberg, Germany. christoph.lichtenstern@med.uni-heidelberg.de
pubmed:publicationType
Journal Article, Review